Bristol Myers' immunotherapy can now be used before and after surgery in the U.S. Elsewhere, J&J, Bayer, Bristol Myers Squibb and Pfizer are trimming staff.

Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.

Over the next three months, the agency could approve a rival to a fast-selling Pfizer heart drug, a much-debated lung cancer medicine and an addition to Vertex's dominant cystic fibrosis business.

The agency will offer earlier meetings with drugmakers as well as solicit more patient feedback on the process.

The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly.

The company will permit six generic drugmakers to make and sell lenacapavir in 120 countries that have high incidence of the disease, but limited resources.

Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies' research progress. Here’s a list of conferences to watch in 2025.

IGM is the latest biotech to focus on the potential for T cell engagers to treat inflammatory conditions. Elsewhere, Metsera signed a manufacturing deal and UCB started a first-of-its-kind trial.

The biotech, which has now raised more than $200 million since launch, is advancing an eczema treatment that could start human trials next year.

The official launch comes five months after a filing indicated major investors such as Atlas Venture and Bain Capital were backing the biotech, then named “Hercules CM NewCo.” ...

The latest investment in the Lebanon site comes after an announcement in May of $5.3 billion earmarked to build production capacity for Lilly’s obesity and diabetes drugs. All told, the company said ...

Cheong points to the broad spectrum of patient demographics in the APAC region for creating substantial opportunities for clinical trial sponsors who are keen to meet enrolment targets at an expedited ...